Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is poised for significant growth, particularly with the approval of additional indications for Dupixent, now projected to reach approximately $21 billion in U.S. peak sales by 2030. The profitability from the Sanofi collaboration is expected to increase notably, with revenue projected to rise by $1 billion in 2027, driven by the repayment of development balances by the third quarter of 2026. Furthermore, the company's robust pipeline, including advancements in allergy programs and expansion in oncology, neurology, and other therapeutic areas, suggests diversified growth prospects beyond its core franchises, supporting a strong financial outlook.

Regeneron Pharmaceuticals is experiencing a negative outlook primarily due to declining sales of EYLEA, impacted by competition from biosimilars and the gradual uptake of EYLEA HD, which compromise revenue stability. Additionally, the company faces significant risks with its development programs, including heightened competition and the possibility of failure to advance pipeline candidates, which may adversely affect future revenue growth and investor confidence. The reliance on Dupixent as a key growth driver is also concerning, as underperformance in expected sales, both domestically and internationally, could further lead to downward adjustments in revenue projections and overall financial performance.